Numerous preclinical and clinical results demonstrate that a constitutively increased activity of ErbB receptors (e.g., EGFR) by mutation (i.e., primarily in non-small cell lung cancer) or gene amplification (in multiple tumor types including head and neck cancer) is responsible for both chemo- and radiation resistance [58, 59]. Here, EGFR is linked to neoplasm.